Insmed reported $20.71B in Market Capitalization this March of 2026, considering the latest stock price and the number of outstanding shares.





Market Capitalization Change Date
BioMarin Pharmaceutical USD 11.76B 348M Mar/2026
Cytokinetics USD 7.77B 1.19B Dec/2025
DBV Technologies USD 274M 17M Sep/2025
Gilead Sciences USD 152.28B 14.55B Dec/2025
Heron Therapeutics USD 133M 105M Mar/2026
Insmed USD 37.12B 6.68B Dec/2025
Novartis USD 246.07B 11.81B Sep/2025
Regeneron Pharmaceuticals USD 81.12B 21.53B Dec/2025
Sarepta Therapeutics USD 2.26B 238M Dec/2025
Ultragenyx Pharmaceutical USD 2.22B 680M Dec/2025
Vertex Pharmaceuticals USD 115.03B 14.61B Dec/2025